Gastrointestinal stromal tumours overexpress fatty acid synthase.

TitleGastrointestinal stromal tumours overexpress fatty acid synthase.
Publication TypeJournal Article
Year of Publication2006
AuthorsRossi S, Ou W, Tang D, Bhattacharya N, Tos APDei, Fletcher JA, Loda M
JournalJ Pathol
Volume209
Issue3
Pagination369-75
Date Published2006 Jul
ISSN0022-3417
KeywordsBiomarkers, Tumor, Blotting, Western, Cell Proliferation, Fatty Acid Synthases, Gastrointestinal Stromal Tumors, Gene Silencing, Humans, RNA, Neoplasm, RNA, Small Interfering, Tumor Cells, Cultured
Abstract

Fatty acid synthase (FASN), a key enzyme for de novo lipogenesis, is overexpressed in many malignant tumours and is associated with aggressive biological behaviour. FASN expression and its possible relationship with more aggressive behaviour in gastrointestinal stromal tumours (GISTs) have not been addressed to date. Here, FASN expression was assessed by immunohistochemistry in 60 primary GISTs (28 low/intermediate risk and 32 high risk) and seven metastatic GISTs. Sixteen smooth muscle gastrointestinal tumours were used as controls. FASN was overexpressed in 36 of 60 GISTs (60%): in 12 of 28 (42%) low/intermediate-risk GISTs and in 24 of 32 (75%) high-risk GISTs (p<0.05). Two primary and seven metastatic GISTs and five GIST cell lines (GIST882, GIST430, GIST522, GIST62, and GIST48), analysed by western blot, showed variable FASN expression. Most metastatic samples expressed high levels of FASN protein. Additionally, seven of 60 GISTs showed a proliferation rate higher than 10% by Ki67 and all of them expressed FASN (p<0.04). Finally, proliferation and apoptosis were investigated after FASN silencing in GIST882 cells, which displayed the highest FASN expression. siRNA-mediated FASN knock-down inhibited expression of the proliferation marker cyclin A, whereas no changes in p27 and cleaved PARP expression were seen. It is concluded that FASN is preferentially overexpressed in high-risk and metastatic GISTs, and that its overexpression likely contributes to cell proliferation.

DOI10.1002/path.1983
Alternate JournalJ Pathol
PubMed ID16583360
Grant ListP01-CA89021 / CA / NCI NIH HHS / United States
P50CA90381 / CA / NCI NIH HHS / United States
Related Faculty: 
Massimo Loda, M.D.

Pathology & Laboratory Medicine 1300 York Avenue New York, NY 10065 Phone: (212) 746-6464
Surgical Pathology: (212) 746-2700